Are You Eligible?

You may be eligible for the study if you fall into one of the following two categories:

You are undergoing or plan to undergo an ovarian stimulation treatment to produce multiple oocytes (eggs) and are interested in preimplantation genetic testing for aneuploidy (PGT-A) of the embryos.

- Or -

You have already undergone ovarian stimulation in the past and have a frozen euploid embryo and you qualify for a frozen embryo transfer (FET).

Eligibility requirements for both groups:

- Age 35-42
- Are planning a single frozen embryo transfer
- Have regular menstrual cycles (24-38 days)
- Do not have history of recurrent pregnancy loss (2 or more consecutive losses)
- Have a BMI of <38 kg/m^2

For a complete list of eligibility criteria, please speak to the study doctor or research nurse at this IVF facility.

If you are interested in learning more about the Progress IVF study, and what compensation you may qualify for by participating, please speak with your IVF doctor or nurse.

Scan the QR code or visit progressivfstudy.com for more details about the study, including information on how to sign up.

IBSA

IN VITRO FERTILIZATION (IVF) RESEARCH STUDY

We're looking for women ages 35–42 to participate in The PROGRESS Study.

IBSA

The PROGRESS Study is an investigational study to determine if Progesterone-IBSA administered as an injection under the skin (subcutaneous) is safe and effective in supporting the implantation and early pregnancy following a frozen embryo transfer (FET).

About the PROGRESS Study

The hormone progesterone plays a vital role in early pregnancy. Our researchers at this IVF clinic are investigating an alternative way to administer progesterone, to discover if subcutaneous (under-the-skin) injections are as safe and effective as the current approved medication, Crinone®. Crinone® is a progesterone gel that is administered vaginally and has been approved by the United States Food and Drug Administration (FDA). The use of Progesterone-IBSA in this study is investigational, which means it is not approved by the FDA. However, Progesterone-IBSA is already approved and marketed in more than 30 countries worldwide.

Compensation for Participation

Qualified study participants will receive the study medications at no cost and a credit/discount applied to their frozen IVF cycle costs.

Credit/discount: If you undergo a frozen embryo transfer you will receive up to $7,500 to cover the costs associated with the transfer and the study related procedures.

In addition to the credits for the frozen embryo transfer:

- If you don't currently have a confirmed euploid embryo for transfer and need to undergo ovarian stimulation you may receive ovarian stimulation medications at no cost to you, a credit up to $5,400 to cover the costs associated with the cycle along with PGT-A testing for embryos and a $2,500 credit toward biopsy costs.
- If you currently have a frozen euploid embryo and don't require ovarian stimulation you may also qualify for a credit/discount for a future cycle if you complete a frozen embryo transfer and don't get pregnant.